Consumer Friendly
Microfluidics
The next big thing in microfluidics is small-very small. The new NeoIMA™ well plate uses nanoliter sample volumes to significantly reduce testing costs.
Cells hanging
Culture cells in 3D with better control in NeoCULTURE™ devices.
Zebra Fish
To stay
Still?
Let NeoMO™ coax your model organism into the right orientation for the perfect image everytime. No anaesthesia, no agar.
About us
Neofluidics develops next-generation tools and technology for enhanced microfluidics. Our engineering-driven products add unprecedented convenience and efficiency to workflows, significantly reducing the costs of testing, measurement, and analysis.
Our applications
NeoONE™ - SYSTEMS
The NeoONE™ System is an integrated instrument for all your drug discovery needs, from immunoassays to 3D cell culture to zebrafish screening. Expected launch - mid 2018.
NeoIMA™ - IMMUNOASSAY
The NeoIMA™ device enables immunoassays to be performed rapidly in nanoliter volumes with minimal matrix effects and high sensitivity.
NeoCULTURE™ - CELL CULTURE
The Neofluidics platform technology allows high throughput 2D and 3D cell culture for deeper insights into cell biology.
NeoMO™ - MODEL ORGANISM
Neofluidics has designed a cutting-edge microfluidics platform technology for high throughout model organism studies.
NeoPS™ - DRUG PREFORMULATION STUDIES
Neofluidics is improving the efficiency and accuracy of preformulation studies
NeoVisc™ - VISCOMETER
The NeoVisc™ microfluidic viscometer uses smartphone technology for real-time measurement of physical properties such as density and viscosity.
Products in Use
Dr. Nihal Mulla, at Drake University is using Neofluidic's technology for 2D and 3D cell culture as well as for the preparation of emulsion-based drug discovery stystems. These formulations will be ready-to-use drug delivery systems with defined parameters such as consistent shape, size, dispersity, charge, encapsulation efficency and stability.
Dr. Vivek Gupta is utilizing Neofluidics' technology for 2D and 3D cell culture as well as to develop and optimize innovative approaches for novel drug delivery systems that will circumvent traditional problems associated with scale-up and in-vivo performance.
Dr. Adam Rich uses the NeoMO™ devices to develop novel zebrafish based models to investigate new treatments for gastrointestinal motility disorders.
